IXICO plc (LSE:IXI) has issued a trading update for the financial year ended September 30, 2025, reporting a 13% year-on-year revenue increase to £6.5 million—surpassing market expectations. The company expanded its commercial pipeline by signing new contracts and renewing existing ones, closing the year with an order book valued at £13.8 million. With £3.5 million in cash at year-end and a successful capital raise, IXICO is directing fresh investment toward strategic growth initiatives.
The company expects to report a slightly improved EBITDA loss of no more than £1.6 million, reflecting continued investment in scaling operations. CEO Bram Goorden highlighted confidence in IXICO’s growth trajectory and its ability to deliver value in the neurodegenerative disease R&D market.
Despite the top-line momentum, the company’s financial outlook remains weighed down by negative profit margins and weak earnings, which dampen its valuation appeal. Strong technical momentum offers some support, though the absence of earnings call and corporate event details limits forward visibility.
About IXICO
IXICO is a global neuroscience imaging and biomarker analytics company leveraging an AI-powered platform to support drug development in neurological diseases. As a full-service Imaging Contract Research Organisation (iCRO), it partners with leading pharmaceutical and biotech companies, as well as research consortia and non-profit organizations, contributing to clinical trials in conditions including Alzheimer’s, Huntington’s, and Parkinson’s disease.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
Leave a Reply